CSIMarket


Agex Therapeutics Inc   (AGE)
Other Ticker:  
 


 

Agex Therapeutics Inc

AGE's Financial Statements and Analysis



Agex Therapeutics Inc increased second quarter of 2023 net loss per share of $-0.07 compare to net loss per share of $-0.07 recorded in the same quarter a year ago a decrease compare to $0.00 realized in previous quarter.


second quarter of 2023
Earnings Per Share Revenues
$ -0.07 $  0 Mill
Unch.     Unch.     -25 %



Agex Therapeutics Inc 's Revenue fell by -25 % in second quarter of 2023 (Jun 30 2023) year on year, to $0 million and declined by -10 % sequentially.


Agex Therapeutics Inc is Expected to report next financial results on March 30, 2024.

More on AGE's Income Statement



Agex Therapeutics Inc 's in thesecond quarter of 2023 recorded net loss of $-2.679 million, an increase from net loss of $-2.618 million in II. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-3.285 million realized in previous quarter.

More on AGE's Growth

Agex Therapeutics Inc Inventories
AGE's Cash flow In the second quarter of 2023 company's net cash flow was $0 million


Agex Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Agex Therapeutics Inc payed $ -0.07 cash per share, on a free-cash flow basis .


Tangible Book value fell to $ -0.60 per share from $ -0.55.

Company issued 0.18 million shares or 0.47 % in Jun 30 2023.


More on AGE's Dividends

 Market Capitalization (Millions) 851
 Shares Outstanding (Millions) 38
 Total Debt (Millions $) 33
 Revenue (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -5
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Agex Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Agex Therapeutics Inc had negative $ -0.07 cash flow per share, on a free-cash flow basis .


Tangible Book value fell to $ -0.60 per share from $ -0.55.

Company issued 0.18 million shares or 0.47 % in Jun 30 2023.


More on AGE's Balance Sheets

 Market Capitalization (Millions) 851
 Shares Outstanding (Millions) 38
 Total Debt (Millions $) 33
 Revenue (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -5
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Agex Therapeutics Inc Earnings

Aging Specialists Agex Therapeutics Inc Report a $-0.07 per Share Deficit in Q2 2023 Due to Declining Business

Declining Business Causes Increase in Deficit for Agex Therapeutics Inc
Agex Therapeutics Inc, a leading biotechnology company specializing in age-related diseases, recently reported its financial results for the fiscal period ending June 30, 2023. The company experienced a notable decline in business, which led to an increase in its deficit.
During the mentioned fiscal period, Agex Therapeutics Inc reported a deficit per share of $-0.07, representing no change from the previous year. This decline was accompanied by a decrease in revenue by -25% to $0.01 million, compared to the $0.01 million revenue recorded the previous year. Additionally, the revenue for the first quarter of 2023 deteriorated by -...

Agex Therapeutics Inc Achieves Balanced Books with $0.01 Million in Revenue for Q1 2023, Showing Promise for Profitability

Agex Therapeutics Inc, a biotechnology company that focuses on developing regenerative therapies, recently released its financial report for the fiscal first quarter of 2023. According to the report, Agex Therapeutics Inc managed to achieve balanced books of $0.00 per share in comparison to a loss of $0.06 per share from the previous year's first fiscal quarter. Moreover, the company's preceding reporting period showed earnings of $0.09 per share.
It is essential to understand that balanced books indicate that a company's revenue and expenses are equal, resulting in no profit or loss. Therefore, the fact that Agex Therapeutics Inc could break even implies that they have managed their finances appropriat...


Date modified: 2023-08-18T15:58:59+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com